Three-Drug attack on tough lung cancer tested in small trial
NCT ID NCT03581487
Summary
This study tested a combination of three drugs—durvalumab, tremelimumab, and selumetinib—for people with advanced or returning non-small cell lung cancer. The goal was to see if using these drugs together could help the immune system fight the cancer and slow its growth better than previous treatments. The trial first aimed to find the safest dose and then see how long patients lived without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.